undamentalytics Newsletter
Sign in

Humacyte, Inc. revenue

Humacyte, Inc.'s revenue was $2.0m in fiscal 2025. Over the last twelve months it was $2.1m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Revenue022
Gross profit0−8−10

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $1.4M 68.2% —
Other $649,000 31.8% —

From Humacyte, Inc.'s 10-K filed March 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Humacyte, Inc. $2.1m 159.3% —
Korsana Biosciences, Inc. $1.9m -12.6% —
Collplant Biotechnologies Ltd $2.4m 360.4% —
Korro Bio, Inc. $2.4m -62.1% -53.7%
Seres Therapeutics, Inc. $1.9m 100.0% -75.6%
Vistagen Therapeutics, Inc. $2.5m 287.3% —

Compare with peers

Head to head: HUMA vs KRSACLGN vs HUMAHUMA vs KRRO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Humacyte, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Humacyte, Inc.